| Literature DB >> 32386552 |
Bjoern Neumann1, Sarah Foerster1, Chao Zhao1, Benedetta Bodini2, Daniel S Reich3, Dwight E Bergles4, Ragnhildur Thóra Káradóttir1, Catherine Lubetzki2, Luke L Lairson5, Bernard Zalc2, Bruno Stankoff2, Robin J M Franklin6.
Abstract
Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.Entities:
Year: 2020 PMID： 32386552 DOI： 10.1016/j.stem.2020.03.017
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633